Common Asthma Drug Shows Promise Against Multiple Cancer Types in Early Research
Similar Articles
Immunotherapy Shows Promise as Pre-Surgery Treatment for Specific Bowel Cancer
Pre-Surgery Immunotherapy Shows Promise for a Subtype of Colorectal Cancer
New Drugs Target 'Zombie' Cells to Combat Cancer and Aging
First Large-Scale Genetic Study of Cat Cancers Reveals Shared Drivers with Humans
First Patient Enrolled in CAR T Cell Therapy Trial for Multiple Sclerosis
A Northwestern University study suggests montelukast, an FDA-approved asthma drug, may help fight aggressive cancers by blocking a molecule that tumors use to evade treatment. In mouse models, blocking this pathway slowed tumor growth, improved survival, and restored response to immunotherapy. The findings, published in Nature Cancer, indicate a potential new approach to enhancing cancer treatment.
Facts First
- Montelukast, a common asthma drug, may help fight aggressive cancers according to new research.
- Tumors exploit a molecule called CysLTR1 to increase immune-suppressing neutrophils and resist treatment.
- Blocking CysLTR1 in mouse models slowed tumor growth, improved survival, and restored immunotherapy response.
- The effect was observed across multiple cancer types including breast, melanoma, ovarian, colon, and prostate cancers.
- Patients with higher CysLTR1 activity tended to have worse survival and poorer immunotherapy response.
What Happened
A research team from Northwestern University's Feinberg School of Medicine identified a molecule called CysLTR1 as a key factor in how tumors evade immunotherapy. The team found that tumors exploit CysLTR1 to increase neutrophils, which helps the tumors grow and resist treatment. In mouse models including triple-negative breast cancer, melanoma, ovarian cancer, colon cancer, and prostate cancer, blocking the CysLTR1 pathway slowed tumor growth and restored response to immunotherapy. The findings were published in the journal Nature Cancer.
Why this Matters to You
This research suggests a potential new strategy to make existing cancer treatments more effective. If future clinical trials confirm these findings, the FDA-approved asthma drug montelukast could potentially be used to improve treatment outcomes for aggressive cancers.
What's Next
The research is preclinical, based on mouse models and human tissue analysis. The next step is likely to involve clinical trials to test whether montelukast can safely and effectively enhance immunotherapy in human patients with cancer. If successful, this could lead to a new, accessible combination therapy for several difficult-to-treat cancers.